Pharmaceutical giant Pfizer has reported second-quarter earnings that beat analysts’ estimates, thanks to strong sales of its newest drugs for cancer and rheumatoid arthritis.
Sales of Ibrance, Pfizer’s new breast cancer treatment, more than tripled to $514m. The drug generated $723m last year, its first on the market, and analysts surveyed by Bloomberg predict annual sales will reach $4.81 billion by 2018.
Second-quarter sales of Pfizer’s rheumatoid arthritis drug Xeljanz were $217m, ahead of...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team